As a cancer-preventative strategy (14) (i.e., prior to the loss of PPARγ expression), the administration of the PPARγ agonists may inhibit the development of a tumor-supportive stroma by targeting angiogenesis, pericyte-to-myofibroblast transition, and adipocyte dedifferentiation. This evidence concerns the gene PPARG and neoplasm.